Biomerica, Inc. (BMRA) |
| 2.71 0.05 (1.88%) 01-13 16:00 |
| Open: | 2.61 |
| High: | 2.71 |
| Low: | 2.61 |
| Volume: | 12,074 |
| Market Cap: | 8(M) |
| PE Ratio: | -1.77 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 3.40 |
| Resistance 1: | 2.91 |
| Pivot price: | 2.64 |
| Support 1: | 2.53 |
| Support 2: | 2.30 |
| 52w High: | 10.16 |
| 52w Low: | 2.11 |
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
| EPS | -1.530 |
| Book Value | 1.830 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.215 |
| Profit Margin (%) | -74.84 |
| Operating Margin (%) | -81.01 |
| Return on Assets (ttm) | -41.5 |
| Return on Equity (ttm) | -69.6 |
Tue, 23 Dec 2025
Biomerica’s Market Presence Expands with Egyptian Drug Authority Authorization - timothysykes.com
Tue, 23 Dec 2025
Biomerica Gains Exposure as Distribution Expands in Egypt - StocksToTrade
Tue, 23 Dec 2025
Medicare sets $300 price for new food-trigger test to ease IBS pain - Stock Titan
Thu, 11 Dec 2025
Biomerica, Inc. Receives Authorization from Egyptian Drug Authority for Comprehensive Cancer and Chronic Disease Screening Portfolio - Quiver Quantitative
Thu, 16 Oct 2025
59.6% of treated patients hit FDA abdominal pain endpoint; Biomerica, Henry Schein to market inFoods® in U.S. (ex NY) - Stock Titan
Wed, 08 Oct 2025
Gary Huff Joins Biomerica Board as Independent Director — Former LabCorp Diagnostics CEO to Advise Growth - Stock Titan
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |